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(HCC) remains poor, highlighting the need for novel therapies.
Genetically modiﬁed mesenchymal stem cells (MSCs) are
actively being explored as cancer therapeutics due to their
inherent ability to migrate to tumor sites. We reasoned that
MSCs can be genetically modiﬁed to redirect T cells to Glypi-
can-3 (GPC3)+ HCC, and genetically modiﬁed these with viral
vectors encoding a GPC3/CD3 bispeciﬁc T cell engager
(GPC3-ENG), a bispecifc T cell engager speciﬁc for an irrelevant
antigen (EGFRvIII), and/or costimulatorymolecules (CD80 and
41BBL).Coculture ofGPC3+ cells,GPC3-ENGMSCs, andT cells
resulted in T cell activation, as judged by interferon g (IFNg)
production and killing of tumor cells by T cells. Modiﬁcation
of GPC3-ENG MSCs with CD80 and 41BBL was required for
antigen-dependent interleukin-2 (IL-2) production by T cells
and resulted in faster tumor cell killing by redirected T cells.
In vivo, GPC3-ENG MSCs ± costimulatory molecules had anti-
tumor activity in theHUH7HCCxenograftmodel, resulting in a
survival advantage. In conclusion, MSCs genetically modiﬁed to
expressGPC3-ENG± costimulatorymolecules redirect T cells to
GPC3+ tumor cells and have potent antitumor activity. Thus,
further preclinical exploration of our modiﬁed approach to
GPC3-targeted immunotherapy for HCC is warranted.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancer
deaths worldwide, with over 500,000 people affected. The majority of
patients are diagnosed with aggressive advanced disease, which has an
overall 5-year survival rate of less than 15%.1 Activating the immune
system for therapeutic beneﬁt holds the promise to improve outcomes
for HCC because it does not rely on the cytotoxic mechanisms of con-
ventional therapies.
Glypican 3 (GPC3),2 a glycophosphatidylinositiol-linked membrane-
associated protein, is a promising immunotherapeutic target for HCC.
It plays an important role in growth and dedifferentiation of HCC,3,4
and is expressed in 67%–90% of tumors, but not in healthy, adult
normal tissues.2,5 The GPC3-speciﬁc monoclonal antibody (mAb)
GC33 has been evaluated in early phase clinical studies. Infusion of
GC33 was safe; however, only limited antitumor activity was observedMolecular T
This is an open access article under the CC BY-NCthat correlated with the intensity of GPC3 expression.6 One strategy to
improve the antitumor activity of GPC3-targeted immunotherapies is
to express GPC3-speciﬁc chimeric antigen receptors (GPC3-CARs) or
T cell receptors on T cells. Indeed, GPC3-speciﬁc T cells had potent
antitumor activity in preclinical HCC models,7–9 and clinical phase I
testing in humans is in progress. However, the broader application
of autologous cell products, such as CAR T cells, may ultimately be
limited because these cell products are not readily available and
require a signiﬁcant “on site” infrastructure to produce.
Allogeneic “off-the-shelf” cell products, including mesenchymal stem
cells (MSCs), have the potential to overcome these limitations.
Human MSCs avoid allorecognition and, due to their inherent ability
to trafﬁc to tumor sites, are actively being explored to deliver cytotoxic
payloads to cancer cells.10–15 For example, for HCC, it has been
shown that production of the chemokines chemokine (C-C motif)
ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 8 (CXCL8)
by HCC promotes MSC migration to tumor sites.16
Here, we report the generation of MSCs that are genetically modiﬁed
to express bispeciﬁc T cell engagers that consist of one single chain
variable fragment (scFv) speciﬁc for GPC3 and a second scFv speciﬁc
for CD3 (GPC3-ENG). MSCs expressing GPC3-ENG (GPC3-ENG
MSCs) redirected T cells to GPC3+ tumor cells, as judged by cytokine
production and cytolytic activity. GPC3-speciﬁc T cell activation by
GPC3-ENG MSCs was further enhanced by the provision of CD80
and 41BBL costimulation. In addition, GPC3-ENG MSCs induced
tumor regression in an HCC xenograft mouse model, which was asso-
ciated with a signiﬁcant survival advantage.RESULTS
GPC3-ENG MSCs Redirect T Cells to GPC3+ Tumor Cells
We genetically modiﬁed human MSCs with VSVG-pseudotyped
lentiviral vector encoding GPC3-ENG and GFP (Figure 1A). Meanherapy: Oncolytics Vol. 6 September 2017 ª 2017 The Authors. 69
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation of GPC3-ENG MSCs
(A) Scheme of lentiviral vector encoding GPC3-ENG and
GFP. (B and C) Representative FACS diagram and sum-
mary data (GPC3-ENGMSCs [n = 6] and NTMSCs [n = 6])
of GFP expression post-transduction. (D) Detection of
GPC3-ENGprotein in media of GPC3-ENG andNTMSCs
after 24 hr of culture (n = 6, performed in duplicates).
Molecular Therapy: Oncolyticstransduction efﬁciency was 93.3% (range: 86.1%–97.8%; n = 6), as
judged by ﬂuorescence-activated cell sorting (FACS) analysis (Figures
1B and 1C). To quantify GPC-ENG molecules in cell culture media,
we developed an ELISA using recombinant GPC3-ENG protein as
a standard. Although individual GPC3-ENG MSCs secreted a mean
of 81 pg (range: 60.4–94.33) of GPC3-ENG protein per cell in
24 hr, no GPC3-ENG protein was detected in the media of non-trans-
duced (NT) MSCs (Figure 1D). Phenotypic analysis of GPC3-ENG
MSCs revealed no signiﬁcant change in phenotype to NT MSCs, as
judged by cell adherence, ﬁbroblast morphology, and expression of
MSC surface markers (CD90 R95%; CD105 R95%; CD45 %1%;
Figure S1).
To demonstrate that GPC3-ENGMSCs redirect T cells to tumor cells
expressing the target antigen, we used GPC3+ (HUH7 and G401) and
GPC3 (A549) cell lines (Figure S2). To show that GPC3-ENG bind
GPC3+ tumor cells as well as T cells, we incubated cells with condi-
tioned media from GPC3-ENG expressing MSCs or NT MSCs. Cells
were then washed and incubated with recombinant GPC3-Fc (for
T cells) or CD3e-Fc (for tumor cells) protein. Bound recombinant
protein was detected with an Fc antibody. The Fc antibody readily
bound to T cells and tumor cells that had been initially incubated
with media GPC3-ENG-expressing MSCs. In contrast, no binding
was detected for cells that had been incubated with media from NT
MSCs, indicating that GPC3-ENGs readily bind to T cells with their
CD3-speciﬁc scFv and to tumor cells with their GPC3-speciﬁc scFv
(Figure S3). For co-culture assays, we generated NT MSCs, GPC3-
ENG MSCs, or MSCs genetically modiﬁed with an ENG molecule
recognizing an irrelevant antigen (EGFRvIII-ENG MSCs). These
were mixed with tumor cells at MSC to tumor cell ratios of 1:3 and
1:10 in the presence of human T cells. After 24 hr, media was collected
and the presence of interferon g (IFNg) and interleukin-2 (IL-2) was
determined by ELISA. GPC3-ENG MSCs induced T cells to produce
signiﬁcant amounts of IFNg (p < 0.05) only in the presence of GPC3+
tumor cells in contrast to EGFRvIII-ENG MSCs (Figure 2A). How-
ever, GPC3-ENG MSCs did not induce T cells to produce IL-2 (Fig-
ure 2B). To assess the ability of GPC3-MSCs to induce T cell killing of
tumor cells, we cocultured MSCs in the presence of T cells and tumor
cells that were genetically modiﬁed to express enhanced GFP (eGFP)70 Molecular Therapy: Oncolytics Vol. 6 September 2017ﬁreﬂy luciferase fusion gene (eGFP.ffLuc).
Although GPC3-ENG MSCs induced T cell
killing of GPC3+ target cells, no T cell killing
of GPC3 target cells was observed (p < 0.001;
Figure 2C). Media, NT MSCs, or EGFRvIII-
ENG MSCs did not induce killing of any targetcells, conﬁrming speciﬁcity. Thus, GPC3-ENGMSCs activate human
T cells in an antigen-dependent manner and induce antigen-depen-
dent tumor cell killing.
GPC3-ENGMSCs Expressing CD80 and 41BBL Induce T Cells to
Produce IL-2 in an Antigen-Dependent Manner
Because we did not observe antigen-dependent IL-2 production, we
next generated GPC3-ENG MSCs that also expressed costimulatory
molecules (CD80, 41BBL, or CD80 and 41BBL) on their cell surface
(Figures S4A and S4B). There was no signiﬁcant difference in re-
gards to GPC3-ENG protein production between different MSC
populations (Figure S4C). We performed co-culture assay as
described above with GPC3-ENG MSC.CD80, GPC3-ENG
MSC.41BBL, or GPC3-ENG MSC.CD80+41BBL at an MSC to tu-
mor cell ratio of 1:10 in the presence of T cells. All MSC populations
induced signiﬁcant production of IFNg by T cells in the presence of
GPC3+ (HUH7 and G401) tumor cells in comparison to GPC3
(A549) tumor cells (p < 0.01; Figure 3A). GPC3-ENG
MSC.CD80+41BBL not only induced the highest IFNg production
by T cells (p < 0.05), but also induced IL-2 production in a
GPC3-dependent manner in contrast to all other MSC populations
(Figure 3B). To further investigate which ratio of MSCs to tumor
cells is needed to induce IFNg and IL-2 production, we performed
a titration experiment. Signiﬁcant IFNg production was observed
at an MSC to tumor cell ratio of 1:30 in contrast to IL-2 production
(Figure S5). Speciﬁcity of GPC3-ENG MSC expressing costimulatory
molecules was further conﬁrmed in 24-hr cytotoxicity assays, with
antigen-speciﬁc target cell killing of up to 60% (Figure 3C). Killing
increased to greater than 99% in a 48-hr cytotoxicity assay
(Figure S6).
GPC3-ENGMSCs InduceAntigen-Dependent TCell Proliferation
We next evaluated whether GPC3-ENG MSCs could induce antigen-
speciﬁc T cell proliferation. GPC3-ENG MSCs ± costimulatory
molecules, NT MSCs, or EGFRvIII-ENG MSCs were cocultured
with tumor cell lines at an MSC to tumor cell ratio of 1:10 in the pres-
ence of human T cells. After 7 days, non-adherent cells were harvested
and the absolute numbers of CD3+ T cells were determined by FACS
analysis. All GPC3-ENG MSC populations induced T cell
Figure 2. GPC3-ENG MSCs Induce T Cells to
Recognize and Kill GPC3+ Tumor Cells
(A and B) GPC3-ENG, EGFRvIII-ENG, or NT MSCs were
cocultured with GPC3+ (G401; HUH7) or GPC3 (A549)
cell lines at 1:10 (left panel) or 1:3 (right panel) MSC to
tumor cell ratios in the presence of human T cells (10:1
T cell to tumor cell ratio). After 24 hr, IFNg (A) or IL-2
(B) was determined by ELISA (n = 6, assay performed in
duplicates; GPC3-ENG versus NT and CD19-ENG
MSCs: *p < 0.05, **p < 0.01, ***p < 0.001). (C) Luciferase-
based cytotoxicity assays using GPC3-ENG, EGFRvIII,
or NT MSCs and GPC3+ (G401.eGFP.ffLuc;
HUH7.eGFP.ffLuc) or GPC3 (A549.eGFP.ffLuc) cell
lines as targets at an MSC to tumor cell ratio of 1:10 in the
presence of human T cells (10:1 T cell to tumor cell ratio;
n = 6; assay was performed in triplicates; box graph;
whiskers: min, max; ***p < 0.001).
www.moleculartherapy.orgproliferation in the presence of GPC3+ (HUH7 and G401) tumor cells
in contrast to media, NT MSCs, or EGFRvIII-ENG MSCs. In the
presence of GPC3 tumors, no T cell proliferation was observed,
conﬁrming speciﬁcity (Figure 4A). Phenotypic analysis revealed pre-
dominance of CD8+ T cells (Figure 4B), and expanded T cells had a
central memory phenotype (CCR7+ CD45RA; Figures 4C and
4D). To conﬁrm that GPC3-ENGs by themselves do not induce
T cell proliferation, T cells were incubated with supernatants of
GPC3-ENG or NT MSCs. Absolute numbers of T cells were enumer-
ated after 72 hr, and no signiﬁcant difference was observed between
both groups (Figure S7).Molecular TGPC3-ENG MSCs.CD80+41BBL Induce
Faster T Cell Killing of GPC3+ Tumor Cells
Having established that GPC3-ENG
MSCs.CD80+41BBL induce more potent
T cell activation, as judged by IL-2 production,
we wanted to determine if this results in faster
tumor cell killing by T cells. To study the
kinetics of tumor cell killing, we used a spinning
disc confocal microscopy assay, in which the
incorporation of propidium iodide (PI) into
dying cells is measured in real time. To quantify
cell death, the area-corrected intensity of PI
ﬂuorescence was calculated. GPC3-ENG
MSCs.CD80+41BBL induced faster T cell
killing of GPC3+ tumor cells in comparison to
GPC3-ENG MSCs (p < 0.001). Neither MSC
population induced T cell killing of GPC3
A549 cells, conﬁrming speciﬁcity (Figures 5A
and 5B; Movies S1 and S2).
GPC3-ENG MSCs Have Antitumor Activity
In Vivo
We ﬁnally compared the antitumor activity of
GPC3-ENG MSCs in vivo. In the ﬁrst set of
experiments, HUH7.eGFP.ffLuc cells werecoinjected subcutaneously (s.c.) at a ratio of 10:1 with GPC3-ENG
MSCs, GPC3-ENG MSC.CD80, GPC3-ENG MSC.41BBL, or GPC3-
ENG MSC.CD80+41BBL. On day 7, mice received an intravenous
(i.v.) dose of 1  107 T cells. HUH7.eGFP.ffLuc coinjected with
EGFRv3-ENG MSC or EGFRvIII-ENG MSC.CD80+41BBL served
as controls. After T cell infusion, there was a signiﬁcant decrease in
tumor growth, as judged by bioluminescence imaging, in mice that
received GPC3-ENGMSCs ± costimulatory molecules in comparison
to control mice (Figures 6A and 6B). This resulted in a signiﬁcant
survival advantage of GPC3-ENG MSCs ± costimulatory molecule
treated mice (p < 0.01; Figure 6C). However, provision ofherapy: Oncolytics Vol. 6 September 2017 71
Figure 3. GPC3-ENG MSCs Expressing CD80 and 41BBL Induce T Cells to
Produce IL-2
(A and B) GPC3-ENG, GPC3-ENG.CD80, GPC3-ENG.41BBL, or GPC3-
ENG.CD80+41BBL MSCs were cocultured with GPC3+ (G401; HUH7) or GPC3
(A549) cell lines in 1:10 MSC to tumor cell ratios in the presence of human T cells
(10:1 T cell to tumor cell ratio). After 24 hr, IFNg (A) or IL-2 (B) was determined by
Molecular Therapy: Oncolytics
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GPC3-ENG MSCs. Next, we determined the antitumor activity of
GPC3-ENG MSCs in established tumors. Mice were injected s.c.
with HUH7.eGFP.ffLuc cells. On day 7, mice received a peritumoral
injection of GPC3-ENG MSC.CD80+41BBL or EGFRvIII-ENG
MSC.CD80+41BBL, followed by an i.v. dose of T cells on day 10. Con-
trols included tumor-bearing mice that only received T cells or GPC3-
ENGMSC.CD80+41BBL. Only GPC3-ENGMSC.CD80+41BBL plus
T cells induced a regression of established tumors, as judged by biolu-
minescence imaging (Figures 7A and 7B). This resulted in a signiﬁ-
cant increase in survival in comparison to mice that only received
T cells (Figure 7C).
DISCUSSION
In this study, we describe the generation of GPC3-ENG MSCs and
demonstrate that these cells redirect T cells to GPC3+ HCC (Fig-
ure S8). Modifying GPC3-ENG MSCs to express CD80 and 41BBL
induced robust IL-2 production, T cell proliferation, and faster
T cell killing of tumor cells in comparison to unmodiﬁed GPC3-
ENG MSCs. In vivo GPC3-ENG MSCs ± costimulatory molecules
had potent anti-tumor activity in an HCC xenograft model.
Several chemo- and irradiation-based therapies have been explored to
improve outcomes for patients with advanced stage HCC in the last
decade.17 Most of them have limited anti-tumor activity, best exem-
pliﬁed by sorafenib, the only Food and Drug Administration
(FDA)-approved drug for the treatment of advanced stage HCC,
which improves overall survival by only 2 months.18 Among different
forms of cell therapies, the infusion of autologous, cytokine-activated
killer (CIK) cells has been explored in numerous clinical studies for
HCC.19 Although CIK cells prolong progression free and overall sur-
vival in the adjuvant setting, their antitumor activity as therapy has
been limited.20 In addition, CIK cells have to be prepared for individ-
ual patients, potentially limiting their broader clinical use. The same
limitations also apply to HCC-speciﬁc cell products, including GPC3-
CAR T cells.
Bispeciﬁc antibodies, T cell ENG or BiTEs, that recognize a tumor
associated antigen (TAA) and CD3 are attractive off-the-shelf prod-
ucts to redirect resident T cells to tumor cells.21 Targeting CD19+
hematological malignancies with CD19-speciﬁc BiTEs has been
very successful in humans, leading to their FDA approval in 2014.22
In contrast, infusion of T cell ENG or BiTEs for solid tumors has
been less effective. Lack of efﬁcacy is most likely due to several factors,
including limited tissue distribution and short half-life of the infused
recombinant protein.23 Expressing T cell ENGs or BiTEs at tumorELISA (n = 6, assay performed in duplicates; GPC3-ENG.CD80+41BBL versus
GPC3-ENG MSCs: *p < 0.05, **p < 0.01, ***p < 0.001). (C) Luciferase-based
cytotoxicity assays using GPC3-ENG, GPC3-ENG.CD80, GPC3-ENG.41BBL, or
GPC3-ENG.CD80+41BBL MSCs and GPC3+ (G401.ffLuc; HUH7.ffLuc) or GPC3
(A549.ffLuc) cell lines as targets at a MSC:tumor ratio of 1:10 in the presence of
human T cells (10:1 T cell to tumor cell ratio; n = 6; performed in triplicates; box
graph; whiskers: min, max; ***p < 0.001).
Figure 4. GPC3-ENG MSCs Induce Antigen-
Dependent T Cell Proliferation
(A–D)GPC3-ENG,GPC3-ENG.CD80,GPC3-ENG.41BBL,
or GPC3-ENG.CD80+41BBL MSCs were cocultured with
GPC3+ (G401; HUH7) or GPC3 (A549) cell lines at a 1:10
MSC to tumor cell ratio in the presence of human T cells
(10:1Tcell to tumorcell ratio). After 7days, absolutenumber
of CD3+ cells (A), CD8/CD4 T cell ratio (B), and presence
of naive (CD45A+,CCR7+), central memory (CM;
CD45A,CCR7+), effectormemory (EM;CD45A,CCR7),
or effector memory RA (EMRA; CD45A+,CCR7) T cells (C
and D) was determined by FACS analysis (n = 4; performed
in duplicates; GPC3-ENG.CD80+41BBL versus GPC3-
ENG MSCs: *p < 0.05, **p < 0.01).
www.moleculartherapy.orgsites should potentially overcome this limitation.24 To accomplish
this, we and others have expressed T cell ENGs or diabodies in autol-
ogous T cells (ENG T cells) that migrate to tumor sites post infu-
sion.24–28 Although ENG T cells have potent antitumor activity in
preclinical models, these cells still have to be prepared for individual
patients.29 To overcome this limitation, we here now have explored
the use of off-the-shelf MSCs to deliver GPC3-ENGs to HCC.
MSCs were readily transduced by lentiviral vectors encoding ENG
molecules and GFP or retroviral vectors encoding costimulatory
molecules, as judged by FACS analysis. Secretion of ENG molecules
was conﬁrmed by ELISA. Although GPC3-ENG MSCs redirectedMolecular TT cells to GPC3+ tumor cells (HUH7 and
G401), as judged by IFNg production, no IL-2
production was observed. This ﬁnding was
consistent with our previous study, in which
IL-2 production of CD19-ENG T cells was
dependent on the presence of co-stimulatory
molecules on the cell surface of tumor cells.26
Because HUH7 and G401 do not express co-sti-
mulatory molecules, such as CD80 and 41BBL
(data not shown), we expressed CD80 and/or
41BBL on the cell surface of GPC3-ENG
MSCs. Expression of CD80 and 41BBL was
required to induce IL-2 production by T cells
in the presence of GPC3+ tumors. Thus, future
studies are needed to understand the require-
ment of CD80 and 41BBL costimulation in
our system because, in general, costimulation
through CD80 alone is sufﬁcient.30 Provision
of costimulation has been shown to improve
the killing capacity of T cells redirected with
ENG molecules to tumor cells.31 Although
G401 and HUH7 cells induced a similar
amount of IFNg and IL-2 production, HUH7
induced greater T cell proliferation than G401
cells; in addition, there were slight differences
in the phenotype of expanded T cells. Cytokine
production is one critical factor that determinesT cell proliferation and phenotype. However, other factors also play a
role, including the absence or presence of inhibitory molecules
expressed (e.g., PD-L1) or secreted (e.g., transforming growth factor
b [TGF-b]) by tumor cells. Further studies are needed to decipher
differences between G401 and HUH7 cells.
Here, we show that costimulation also improves the killing kinetics of
redirected T cells, highlighting another advantage of providing costi-
mulation. However, after 24 and 48 hr, no signiﬁcant killing differ-
ence in conditions ± costimulation was observed. This most likely
is explained by assay differences (ﬂuorescence microscopy versus
luciferase based). In addition, after 48 hr, greater than 99% of targetherapy: Oncolytics Vol. 6 September 2017 73
AB
Figure 5. Time-Lapse Confocal Microscopic
Imaging of GPC3-ENG MSCs Induced Killing of
GPC3+ Tumor Cells
(A) Representative images (at 0 hr and 12 hr) for real-
time detection of cytolytic activity of T cells in the
presence of GPC3+ (HUH7) or GPC3 (A549) cell lines
and GPC3-ENG.CD80+41BBL MSCs (green; 1:10
MSC to tumor cell ratio; 10:1 T cell to tumor cell ratio).
Cell death was visualized by incorporation of PI (red).
(B) Tumor cell killing at various time points was
determined as an area of corrected mean pixel in-
tensity (PI channel; intensity  area  106 pixel). The
solid lines in the graph represent the “best-fit” linear
regression analysis (HUH7 coculture with GPC3-ENG
[blue] or GPC-ENG.CD80+41BBL MSCs [red]; A549
cells coculture with GPC3-ENG [green] or GPC-
ENG.CD80+41BBL MSCs [yellow]. The dots show in-
dividual experimental values (n = 5; experiments = 2;
***p < 0.001).
Molecular Therapy: Oncolyticscells were killed for all GPC3-ENG MSC conditions tested. In our
study, we expressed CD80 and 41BBL on the cell surface of MSCs.
It might be advantageous to genetically modifyMSCs to secrete fusion
molecules that consist of a tumor-speciﬁc scFv and the extracellular
domain costimulatory ligands32 so that T cells receive costimulation
directly at the tumor cells. Future studies are planned to explore
this approach.
In vivo, coinjection of tumor cells and GPC3-ENGMSCs followed by
T cell injection on day 7 resulted in robust antitumor activity of
GPC3-ENG MSCs. However, tumors eventually progressed. To un-
derstand the mechanisms of tumor progression, we determined the
persistence of eGFP.ffLuc-expressing MSCs in vivo. MSCs persisted
for less than 28 days (Figure S9), highlighting the need to administer
multiple doses of MSCs. Although, in this “proof of concept” study,74 Molecular Therapy: Oncolytics Vol. 6 September 2017we did not explore multiple dosing schedules
of MSCs, this is the goal of future studies. Pro-
vision of costimulation did not improve the
anti-tumor activity of GPC3-ENG MSCs;
indeed, expression of 41BBL decreased the anti-
tumor activity of GPC3-ENG MSCs. Several
factors have to be considered, including MSC
and T cell dose, and experiments are in progress
to address this. In addition, mechanistic studies
in regards to the role of 41BBL in our system are
needed. This should include studying the T cell
inﬁltrate within tumors.
In our second in vivo model, we focused on
the peritumoral injection of MSCs, because,
as reported by others,33 systemic i.v. adminis-
tration of human MSCs resulted in the trap-
ping of MSCs in the lung of mice (Figure S10).
Although we injected MSCs peritumoral, there
could be an “abscopal effect” to distant tumorsites. We plan to explore this in future studies, in which mice will
bear a second ﬂank tumor that is not treated. Intra-arterial admin-
istration has been shown to signiﬁcantly improve the systemic
distribution of human MSCs in xenograft models34 and could be
explored in future studies. However, at present, it is unclear if the
observed biodistribution of human MSCs in mice closely mimics
their biodistribution in humans.35 Moreover, the preferred route
of GPC3-ENG MSC administration for HCC patients will most
likely depend on the clinical scenario. For example, although i.v.
administration would be ideal for the therapy of lung disease, the
commonest site of HCC metastases,36 intra-arterial administration
would be the route of choice for locally advanced stage disease,
akin to trans-arterial chemo embolization (TACE), which is
commonly used to deliver chemotherapeutic agents directly into
locally advanced HCC.37
Figure 6. GPC3-ENG MSCs Redirect T Cells In Vivo
to Kill HCC
Antitumor activity of GPC3-ENG MSCs in an HCC
xenograft model. Mice were s.c. coinjected with 5  106
HUH7.eGFP.ffLuc cells and 5  105 GPC3-ENG (n = 5),
GPC3-ENG.CD80 (n = 4), GPC3-ENG.41BBL (n = 5),
GPC3-ENG.CD80+41BBL (n = 5), EGFRvIII-ENG (n = 5),
or EGFRvIII-ENG.CD80+41BBL (n = 5) MSCs on their left
lower flank. On day 7, mice received an i.v. dose of
1  107 T cells. Tumor growth was followed by biolumi-
nescence imaging. (A) Representative images of animals
(red arrow: T cell injection). (B) Quantitative biolumines-
cence imaging results (solid lines: individual mice; radi-
ance = photons/s/cm2/sr). (C) Kaplan-Meier survival
curve (control versus treatment groups; *p < 0.05,
**p < 0.01, ***p < 0.001).
www.moleculartherapy.orgOur study signiﬁcantly extends studies by others. Compte et al.38
genetically modiﬁed MSCs to express a CEA bispeciﬁc diabody, a bis-
peciﬁc mAb format that requires the expression of two genes. CEA
bispeciﬁc diabody-secreting MSCs activated T cells, as evidenced by
antigen-speciﬁc T cell proliferation. In vivo, implanted, MSC-seeded
scaffolds supported diabody production and had antitumor activity in
a colon cancer xenograft model. Aliperta et al.39 genetically modiﬁed
the immortalized MSC line SCP-1 to express CD133-speciﬁc T cell
ENG and 41BBL. CD133-ENG MSCs redirected T cells to CD133+
acute myeloid leukemia (AML) cells, and 41BBL expression enhanced
cytokine production and T cell proliferation in vitro. Ex vivo treat-
ment of AML cells with CD133-ENG MSC.41BBL and T cells
prevented engraftment of AML cells in NSG mice.39 Like the two
previous studies, our study is limited by relying on a xenograft model.
Although these do not recapitulate the immunosuppressive microen-
vironment created by tumors, including HCC,40 they are ideal to
study the interactions of human tumor cells, human MSCs, and
human T cells, which is critical for future clinical development.Molecular TIn summary, our study demonstrates thatMSCs
genetically modiﬁed to express GPC3-ENG ±
costimulatory molecules redirect T cells to
GPC3+ tumor cells and have potent antitumor
activity. Thus, GPC3-ENG MSCs may be a
promising “off-the-shelf cell therapy alterna-
tive” to current GPC3-targeted immunotherapy
approaches that either rely on the passive infu-
sion of antibodies or the adoptive transfer of
autologous CAR T cells.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
G401 (rhabdoid tumor, ATCC) and HUH7
(hepatocellular carcinoma, a gift from Dr.
Xiao-Tong Song, Baylor College of Medicine)
were used as GPC3+ targets. The identity of
HUH7 was conﬁrmed by the Characterized
Cell Line Core Facility at MD Anderson CancerCenter. A549 (lung carcinoma, ATCC) cells were used as negative
controls. 293T cells (ATCC) were used for packaging viral vectors.
HUH7, A549, and 293T cell lines were grown in DMEM (Thermo
Scientiﬁc), G401 in alpha-MEM (Thermo Scientiﬁc) media supple-
mented with 10%–20% fetal bovine serum (FBS) (Thermo Scientiﬁc),
and 2 mmol/L GlutaMAX-I (Invitrogen). The generation of
eGFP.ffLuc-expressing HUH7, G401 and A549 cells has been previ-
ously described.8 Human MSCs from healthy donors were obtained
under a Baylor College of Medicine institutional review board
(IRB)-approved protocol after informed consent was obtained in
accordance to the Declaration of Helsinki. MSCs were cultured in
aMEM (Lonza) supplemented with 20% FBS (Thermo Scientiﬁc)
and 2 mmol/L GlutaMAX-I (Invitrogen; complete aMEM).
Construction of Viral Vectors Encoding T Cell ENG and
Costimulatory Molecules
To generate a GPC3-speciﬁc T cell ENGmolecule, a mini gene encod-
ing the immunoglobulin (Ig) heavy-chain leader peptide and theherapy: Oncolytics Vol. 6 September 2017 75
Figure 7. GPC3-ENGMSCsHave Anti-tumor Activity
in Established Tumors
Mice were s.c. injected with 1  106 HUH7.eGFP.ffLuc
cells on their left lower flank (n = 10). On day 7, mice
received a peritumoral injection of 1  106 GPC3-
ENG.MSC.CD80+41BBL. On day 10, five mice received
an i.v. dose of 1  107 T cells. Tumor-bearing mice
injected with EGFRvIII-ENGMSC.CD80+41BBL (n = 5) or
T cells (n = 5) served as controls. Tumor growth was
followed by bioluminescence imaging. (A) Representative
images of animals (green arrow:MSC injection; red arrow:
T cell injection). (B) Quantitative bioluminescence imaging
results (solid lines: individual mice; radiance = photons/s/
cm2/sr). (C) Kaplan-Meier survival curve (control versus
treatment groups; *p < 0.05).
Molecular Therapy: OncolyticsGPC3-speciﬁc scFv (GC33) was synthesized by Thermo Fisher Scien-
tiﬁc.41 This mini gene was subcloned into an SFG retroviral vector
containing a short serine-glycine linker and a CD3-speciﬁc scFV
derived from OKT3.24 The GPC3-ENG was then subcloned into
pCDH-CMV-MCS-EF1-GFP (SystemBiosciences). The lentiviral vec-
tor encoding the EGFRvIII-speciﬁc T cell ENG was generated in a
similar fashion using the EGFRvIII-speciﬁc scFv 139.42 Lentiviral par-
ticles were generated in 293T cells using packaging plasmids (pPACK
Lentivector Packaging System, System Biosciences) according to the
manufacturer’s instructions. MSCV retroviral vectors encoding
CD80, 41BBL, or 41BBL and CD80 were generated by subcloning76 Molecular Therapy: Oncolytics Vol. 6 September 2017CD80 from pORF.CD80 (InvivoGen) and/or
41BBL from pORF.41BBL (InvivoGen) into
MSCV-I-GFP(M) (provided by the late Elio Va-
nin,NorthwesternUniversity Feinberg School of
Medicine). VSV-G-pseudotyped retroviral par-
ticles were generated as previously described.43
Generation of Genetically Modified MSCs
MSCs were grown to 60%–70% conﬂuency in
T75 ﬂasks and transduced with viral vectors at
an MOI of 10 and 4 mg/mL polybrene (Sigma-
Aldrich). After transduction, MSC were
expanded for 3–5 days prior to use.
Flow Cytometric Analysis
20,000 cells per sample were analyzed by a
FACSCalibur instrument (BD Biosciences) us-
ing Cell Quest Software (BD Biosciences) and
a BD Canto II instrument (BD Biosciences) us-
ing FACSDiva software (BD Biosciences) and
analyzed using Kaluza Analysis 1.3 (Beckman
Coulter) and FlowJo v10 (FlowJo LLC). For
phenotyping MSCs, the following MAbs were
used: CD105-PE (Miltenyi Biotec), CD45-
PerCP and CD90-APC (BD Biosciences),
41BBL-PE (BD Biosciences), and CD80-PerCP
(eBioscience). For phenotyping T cells, thefollowing MAbs were used: CD3-APC, CD4-PE, CD8-APC, CCR7-
FITC, and CD45RA-APC (all BD Biosciences). GPC3 expression of
tumor cell lines was detected with YP7 mAb, which was provided
by Mitchell Ho (NIH).44 Isotype controls included IgG1-PE, IgG1-
PerCP, and IgG1-APC (both from BD Biosciences). Absolute T cell
numbers were calculated using CountBright Absolute Counting
Beads (Thermo Fisher Scientiﬁc).
ELISA
NT and GPC3-ENG ± costimulatory molecules MSCs were plated in
a 12-well plate at a concentration of 5 104/well in 2 mL of complete
www.moleculartherapy.orgaMEM and cultured for 24 hr. To determine the ENG concentration
in conditioned media, we ﬁrst coated 96-well non-tissue culture
treated plates with human recombinant GPC3 protein (R&D Sys-
tems) at 10 ng/well. Media from ENG-MSCs was plated and allowed
to incubate for 1 hr at room temperature (RT). Goat anti-mouse
F(ab’) (Jackson ImmunoResearch) was added and incubated at RT
for 1 hr. The plate was washed, and secondary anti-goat horseradish
peroxidase (HRP) antibody (Jackson ImmunoResearch) was added.
After 1 hr incubation at RT, the plate was washed and developing
agent was added (tetramethylbenzidine [TMB] substrate, Sigma-
Aldrich). Absorbance was read at 450 nm. A standard curve was
generated using recombinant GPC3-ENG protein (custom synthesis;
Thermo Fisher Scientiﬁc).
Coculture Assays
GPC3-ENG MSCs ± costimulatory molecules and EGFRvIII-ENG
MSCs were plated at a 1:3 or 1:10 ratio with GPC3+ (HUH7 and
G401) or GPC3 (A549) target cells. T cells, isolated from peripheral
blood mononuclear cells (PBMCs) by CD3 selection (Miltenyi), were
added at a 10:1 effector to target ratio. Coculture supernatant was
collected after 48 hr and used for cytokine analysis. IFNg and IL-2
concentrations were determined using ELISA kits (R&D Systems),
according to the manufacturer’s instructions.
Cytotoxicity Assay
Cytotoxic activity of T cells against targets was determined by a
luciferase-based cytotoxicity assay. HUH7, G401, and A549 cells
expressing eGFP/ffLuc were plated in 96-well ﬂat bottom plates at a
concentration of 1  104 cells/well in triplicates. GPC3-ENG
MSCs ± costimulatory molecules and EGFRvIII-ENG MSCs were
plated at a 1:10 MSC to tumor cell ratio, and T cells, isolated from
PBMCs by CD3 selection (Miltenyi), were added at a 10:1 effector
to target ratio. Wells without MSCs served as controls. After 24 hr,
luciferase activity was determined using a luciferase assay kit accord-
ing to the manufacturer’s instructions (Promega) and an Inﬁnite
M200 luminometer (Tecan Trading AG).
Time-Lapse Confocal Microscopic Imaging and Image Analysis
MSC-induced target cell killing was quantitatively analyzed by a spin-
ning disk confocal microscope (Zeiss) equipped with a CSU-X1A
5000 spinning disk unit (Yokogowa Electric Corporation) multi-laser
module with wavelengths of 458 nM, 488 nM, and 514 nM and an
Axio Observer Z1 motorized inverted microscope equipped with a
precision motorized XY stage (Carl Zeiss MicroImaging). Tempera-
ture was maintained at 37C and 5% CO2 using an environmental
control chamber. Zen 2012 software (Zeiss) was used to acquire
images in time-lapse mode using a Zeiss Plan-Neoﬂuar 20  0.4
NA objective on an Orca R2 CCD camera and to analyze average
GFP and PI intensity. A quantitative digital image processing pipe-
line, created in ImageJ (W.S. Rasband, NIH [1997–2014]), was used
to calculate speciﬁc PI incorporation of HUH7 and A549 cells. First,
background intensities of PI channel were subtracted; then, raw
images were thresholded based on their intensity histogram. The
same threshold was used on all analyzed images. PI incorporationwas determined as a multiplication of the mean pixel intensity and
thresholded area.
In Vivo Experiments
Animal experiments were performed on a protocol approved by the
Baylor College of Medicine Institutional Animal Care and Use Com-
mittee in accordance with the American Association for Laboratory
Animal Science. Co-injection of tumor cells and MSCs: 8- to
10-week-old NSG mice (NOD.Cg-Prkdcscid/Il2rgtm1Wjl/SzJ; JAX
Mice) were s.c. injected with 5  106 HUH7.eGFP.ffLuc cells and
5  105 gene-modiﬁed MSCs on their left lower ﬂank. On day 7,
mice were injected i.v. with 1 107 T cells. Sequential injection of tu-
mor cells and MSCs: 1  106 HUH7.eGFP.ffLuc cells were injected
s.c. on day 0, and 1  106 gene-modiﬁed MSCs were injected peritu-
moral on day 7. On day 7, mice were injected i.v. with 1 107 T cells.
To generate sufﬁcient T cells for in vivo experiments, T cells were acti-
vated from PBMCs with OKT3 (CRL-8001, ATCC) and CD28 (BD
Biosciences) antibodies and expanded with recombinant human
IL-7 and IL-15 (IL-7, 10 ng/mL; IL-15, 5 ng/mL; Proleukin; Chiron)
for 7–10 days. Mice were imaged using the IVIS system (IVIS, Xeno-
gen), as previously described,45 and euthanized at predeﬁned
endpoints or when they met euthanasia criteria in accordance with
the Center for Comparative Medicine at Baylor College of Medicine.
Statistical Analysis
GraphPad Prism 5 software (GraphPad) was used for statistical
analysis. Data were presented as mean ± SD or SEM. For comparison
between two groups, a two-tailed t test was used. For comparisons of
three or more groups, one-way ANOVA with Bonferroni’s post-test
was used. For comparison of PI incorporation, linear regression
analysis was performed. For the mouse experiments, survival, deter-
mined from the time of tumor cell injection, was analyzed by the
Kaplan-Meier method and log-rank test.
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